GRIbenzinga

GRI Bio Reports Interim Biomarker Results From Phase 2a Study Evaluating GRI-0621 In Idiopathic Pulmonary Fibrosis; Independent Data Monitoring Committee Recommended Study Continue As Planned, As No Safety Concerns Were Seen In The Data Reviewed

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 8, 2025 by benzinga